Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

M Del Re; P Bordi; I Petrini; E Rofi; F Mazzoni; L Belluomini; E Vasile; G Restante; F Di Costanzo; A Falcone; A Frassoldati; Ron van Schaik; Christi Steendam; A Chella; M Tiseo; R Morganti; R Danesi

doi:10.18632/oncotarget.20947

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

M Del Re, P Bordi, I Petrini, E Rofi, F Mazzoni, L Belluomini, E Vasile, G Restante, F Di Costanzo, A Falcone, A Frassoldati, Ron van Schaik, Christi Steendam, A Chella, M Tiseo, R Morganti, R Danesi

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

6 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	86056-86065
Number of pages	10
Journal	Oncotarget
Volume	8
Issue number	49
DOIs	https://doi.org/10.18632/oncotarget.20947
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.18632/oncotarget.20947

REPUB_102461.pdfFinal published version, 2.35 MB

http://hdl.handle.net/1765/102461

Cite this

Del Re, M., Bordi, P., Petrini, I., Rofi, E., Mazzoni, F., Belluomini, L., Vasile, E., Restante, G., Di Costanzo, F., Falcone, A., Frassoldati, A., van Schaik, R., Steendam, C., Chella, A., Tiseo, M., Morganti, R., & Danesi, R. (2017). Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Oncotarget, 8(49), 86056-86065. https://doi.org/10.18632/oncotarget.20947

@article{c0987938bf0c48ee8cb161593bfa3c76,

title = "Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment",

author = "{Del Re}, M and P Bordi and I Petrini and E Rofi and F Mazzoni and L Belluomini and E Vasile and G Restante and {Di Costanzo}, F and A Falcone and A Frassoldati and {van Schaik}, Ron and Christi Steendam and A Chella and M Tiseo and R Morganti and R Danesi",

year = "2017",

doi = "10.18632/oncotarget.20947",

language = "Undefined/Unknown",

volume = "8",

pages = "86056--86065",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "49",

}

Del Re, M, Bordi, P, Petrini, I, Rofi, E, Mazzoni, F, Belluomini, L, Vasile, E, Restante, G, Di Costanzo, F, Falcone, A, Frassoldati, A, van Schaik, R, Steendam, C, Chella, A, Tiseo, M, Morganti, R & Danesi, R 2017, 'Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment', Oncotarget, vol. 8, no. 49, pp. 86056-86065. https://doi.org/10.18632/oncotarget.20947

TY - JOUR

T1 - Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

AU - Del Re, M

AU - Bordi, P

AU - Petrini, I

AU - Rofi, E

AU - Mazzoni, F

AU - Belluomini, L

AU - Vasile, E

AU - Restante, G

AU - Di Costanzo, F

AU - Falcone, A

AU - Frassoldati, A

AU - van Schaik, Ron

AU - Steendam, Christi

AU - Chella, A

AU - Tiseo, M

AU - Morganti, R

AU - Danesi, R

PY - 2017

Y1 - 2017

U2 - 10.18632/oncotarget.20947

DO - 10.18632/oncotarget.20947

M3 - Article

SN - 1949-2553

VL - 8

SP - 86056

EP - 86065

JO - Oncotarget

JF - Oncotarget

IS - 49

ER -